Evaluation of 131I-anti-MIF mAb as a reporter for allograft rejection

In vivo Toll-like receptor 5 (TLR5) imaging with radiolabeled anti-TLR5 monoclonal antibody in rapamycin-treated mouse allogeneic skin transplantation model

BACKGROUND

In organ transplantation, increasing evidence, both in experimental and human studies, indicates that Toll-like receptor (TLR) activation is involved in the innate immune recognition of allograft. TLR5, the only protein recognition receptor of TLRs, is indicated potentially to be the immune regulation target. This study was designed to determine whether TLR5 could be a biomarker for in vivo allograft visualization, after immunosuppressant rapamycin treatment, using radiolabeled sodium iodide ((131) I)-anti-TLR5 monoclonal antibody (mAb).

METHODS

BALB/c mice were transplanted with C57BL/6 skin, with/without rapamycin treatment (the rapamycin-treated group and the phosphate buffered saline [PBS]-rejection group, respectively). In vivo dynamic whole-body phosphor-autoradiography and ex vivo biodistribution studies were conducted after (131) I-anti-TLR5 mAb injection.

RESULTS

Dynamic phosphor-autoradiography imaging showed clear graft localization from 12 h onward. At 72 h after injection, graft uptake quantified from images was higher for the rapamycin-treated group (26,448 ± 904 digital light units [DLU]/mm(2) ), compared with the PBS-treated allo-rejection group (9176 ± 576 DLU/mm(2) ). Treatment with anti-TLR5 mAb inhibited graft uptake. Organ biodistribution study reflected the same tendency, and (131) I-anti-TLR5 mAb uptake reached a maximum of 12.05 ± 1.86 %ID/g (percent injected dose per gram) at 1 h, and graft-to-native skin ratio reached 8.10 ± 0.10 %ID/g at 72 h after injection in rapamycin-treated grafts.

CONCLUSION

Radiolabeled anti-TLR5 mAb showed higher uptake in allo-treated grafts compared with allo-rejection grafts, which was proved by non-invasive dynamic phosphor-autoradiography imaging, and invasive ex vivo biodistribution. Radiolabeled anti-TLR5 mAb is a new tracer for non-invasive in vivo imaging of TLR5 in rapamycin-treated allograft.

Noninvasive allograft imaging of acute rejection: evaluation of (131)I-anti-CXCL10 mAb

The purpose of this study was to investigate the use of iodine-131-labeled anti-CXCL10 mAb as tracer targeted at CXCL10 to detect acute rejection (AR) with mice model. Expression of CXCL10 was proved by RT-PCR, ELISA, and immunochemistry staining. All groups were submitted to whole-body autoradioimaging and ex vivo biodistribution studies after tail vein injection of (131)I-anti-CXCL10 mAb. The highest concentration/expression of CXCL10 was detected in allograft tissue compared with allograft treated with tacrolimus and isograft control. Tacrolimus could obviously inhibit the rejection of allograft. Allograft could be obviously imaged at all checking points, much clearer than the other two groups. The biodistribution results showed the highest uptake of radiotracer in allograft. T/NT (target/nontarget) ratio was 4.15 ± 0.25 at 72 h, apparently different from allograft treated with tacrolimus (2.29 ± 0.10), P < 0.05. These data suggest that CXCL10 is a promising target for early stage AR imaging and (131)I-CXCL10 mAb can successfully image AR and monitor the effect of immunosuppressant.

Non-invasive imaging of allogeneic transplanted skin graft by 131I-anti-TLR5 mAb

Although ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) uptake can be used for the non-invasive detection and monitoring of allograft rejection by activated leucocytes, this non-specific accumulation is easily impaired by immunosuppressants. Our aim was to evaluate a ¹³¹I-radiolabelled anti-Toll-like receptor 5 (TLR5) mAb for non-invasive in vivo graft visualization and quantification in allogeneic transplantation mice model, compared with the non-specific radiotracer ¹⁸F-FDG under using of immunosuppressant. Labelling, binding, and stability studies were performed. BALB/c mice transplanted with C57BL/6 skin grafts, with or without rapamycin treatment (named as allo-treated group or allo-rejection group), were injected with ¹³¹I-anti-TLR5 mAb, ¹⁸F-FDG, or mouse isotype ¹³¹I-IgG, respectively. Whole-body phosphor-autoradiography and ex vivo biodistribution studies were obtained. Whole-body phosphor-autoradiography showed ¹³¹I-anti-TLR5 mAb uptake into organs that were well perfused with blood at 1 hr and showed clear graft images from 12 hrs onwards. The ¹³¹I-anti-TLR5 mAb had significantly higher graft uptake and target-to-non-target ratio in the allo-treated group, as determined by semi-quantification of phosphor-autoradiography images; these results were consistent with ex vivo biodistribution studies. However, high ¹⁸F-FDG uptake was not observed in the allo-treated group. The highest allograft-skin-to-native-skin ratio (A:N) of ¹³¹I-anti-TLR5 mAb uptake was significantly higher than the ratio for ¹⁸F-FDG (7.68 versus 1.16, respectively). ¹³¹I-anti-TLR5 mAb uptake in the grafts significantly correlated with TLR5 expression in the allograft area. The accumulation of ¹³¹I-IgG was comparable in both groups. We conclude that radiolabelled anti-TLR5 mAb is capable of detecting allograft with high target specificity after treatment with the immunosuppressive drug rapamycin.

rFliC prolongs allograft survival in association with the activation of recipient Tregs in a TLR5-dependent manner

Allorejection remains an obstacle for successful organ transplantation. Although different types of immunosuppressive agents are effective for controlling rejection and prolonging graft survival, drug treatment is limited because of side effects and toxicity. Therefore, it is necessary and urgent to identify new candidate drugs for inducing allotolerance. Recently, it has been reported that bacterial flagellin induces the immunosuppressive activity of regulatory T cells (Tregs) in humans in vitro. In the present study, we analyzed the effects of recombinant flagellin (rFliC) on allograft survival and explored the underlying mechanisms associated with the activation of recipient Tregs in a murine skin allotransplantation model. The results showed that rFliC administration (3 mg/kg, once per day for 3 days, i.p.) prolonged allograft survival (mean survival time: 18.4±1.1 days) compared to the control group (10±0.7 days, P<0.01). Additionally, higher positive expression of Toll-like receptor 5 (TLR5) was detected within the allograft administered with rFliC. The frequency of CD4(+)CD25(+)Foxp3(+) Tregs; the expression of Treg-related factors TLR5, Foxp3, TGF-β1 and IL-10; and the proliferation and suppression of Tregs were increased following rFliC administration compared to the control. Moreover, the increased expression of tolerance-related molecules and the proliferation of Tregs induced by rFliC were attenuated by an anti-TLR5 blocking antibody both in vivo and in vitro. In conclusion, rFliC administration prolongs the survival of allografts, which is associated with the activation of recipient Tregs in a TLR5-dependent manner. rFliC may be a new candidate for anti-allorejection therapy.

Evaluation of (131)I-anti-angiotensin II type 1 receptor monoclonal antibody as a reporter for hepatocellular carcinoma

Background

Finding a specific agent is useful for early detection of tumor. Angiotensin II type 1 receptor (AT₁R) was reported to be elevated in a variety of tumors and participate in tumor progression. The aim of our study was to evaluate whether ¹³¹I-anti-AT₁R monoclonal antibody (mAb) is an efficient imaging reporter for the detection of hepatocellular carcinoma.

Methodology/Principal Findings

AT₁R mAb or isotype IgG was radioiodinated with ¹³¹I and the radiochemical purity and stability of the two imaging agents and the affinity of ¹³¹I-anti-AT₁R mAb against AT₁R were measured. 3.7 MBq ¹³¹I-anti-AT₁R mAb or isotype ¹³¹I-IgG was intravenously injected to mice with hepatocellular carcinoma through tail vein, and then the whole-body autoradiography and biodistribution of the two imaging agents and the pharmacokinetics of ¹³¹I-anti-AT₁R mAb were studied. ¹³¹I-anti-AT₁R mAb and ¹³¹I-IgG were successfully radioiodinated and both maintained more stable in serum than in saline. The ¹³¹I-anti-AT₁R mAb group showed much clearer whole-body images for observing hepatocellular carcinoma than the ¹³¹I-IgG group. The biodistributions of the two imaging agents suggested that hepatocellular carcinoma tissue uptook more ¹³¹I-anti-AT₁R mAb than other tissues (%ID/g = 1.82±0.40 and T/NT ratio = 7.67±0.64 at 48 h), whereas hepatocellular carcinoma tissue did not selectively uptake ¹³¹I-IgG (%ID/g = 0.42±0.06 and T/NT ratio = 1.33±0.08 at 48 h). The pharmacokinetics of ¹³¹I-anti-AT₁R mAb was in accordance with the two-compartment model, with a rapid distribution phase and a slow decline phase. These results were further verified by real-time RT-PCR, immunohistochemistry staining and Western blot.

Conclusions/Significance

¹³¹I-anti-AT₁R mAb may be a potential target for early detection of tumor.

Combination of liquid scintillation counting and passive sampling strategy for the determination of ¹³¹I in air and application to estimate the inhalation dose to the staff of a nuclear medicine service

(131)I, commonly used in nuclear medicine, can be incorporated into the human body in a variety of chemical and physical forms. This study describes a sensitive method for the determination of (131)I concentration and its application to the estimation of the amount of airborne (131)I inhaled by staff workers of a Nuclear Medicine Department. Our method uses passive sampling with charcoal canisters followed by liquid scintillation counting, a very sensitive technique for the determination of low concentrations of airborne (131)I. We have studied the effects caused on the measured (131)I concentration in air by both, the doses administered to the patients and the distance of sampling canisters to the patient. We have found a direct relationship between the amount of (131)I activity administered and the airborne (131)I activity concentration. We have estimated the contribution of inhaled (131)I to the effective dose received by staff, finding differences between physicians and non-physician personnel. However, the measured exposure was quite low in both cases, thus suggesting that there is no need to introduce additional safety measures to the current ones.